News

Indaflex is currently in phase II clinical development in Canada for the treatment of osteoarthritis. The cream makes use of AlphaRx’ formulation technology to deliver the active ingredient,

The collaboration will leverage proprietary technology from both organizations to identify favorable targets amenable to drug discovery. Under the five-year research agreement, Myriad will use its genetics, RNA

Many viruses, such as influenza, are surrounded by a single lipid membrane, or envelope, and to enter cells this membrane must be removed. Previously, all enveloped viruses were

The clinical trial, which is being undertaken at Maisonneuve-Rosemont Hospital in Montreal, will consist of 30 patients in two cohorts. Each cohort will receive PBI-1402 or placebo for

The study, published in the Journal of Consumer Research, shows that consumers exposed to marketing for remedies – including smoking cessation and debt consolidation programs – are more

Under the terms of the agreement, Miraculins will combine its internal research expertise with the research capabilities and patient network of Duke University Medical Center (DUMC). The collaboration

The new data provides additional insight into the drug’s mechanism of action, which is believed to inhibit tumor growth, bone metastases and angiogenesis. Results indicate that Abegrin’s mechanism

In December 2003, Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-142886, for co-development and commercialization with AstraZeneca. MEK is a critical enzyme

After the companies complete feasibility studies, InNexus will have a right to license one of Affimed’s antibodies, while Affimed will have the right to license the SuperAntibody technology